drugset / Trial / NCT06104592
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Phase 2
Recruiting
27 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
Timeline
- Start
- 2023-11-08
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Axicabtagene Ciloleucel | Cell therapy | — | — |